<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407016</url>
  </required_header>
  <id_info>
    <org_study_id>A6831006</org_study_id>
    <nct_id>NCT01407016</nct_id>
  </id_info>
  <brief_title>A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects</brief_title>
  <official_title>A Phase 1, Open Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Following Single And Multiple Intravenous Infusion In Healthy Japanese Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics of
      metronidazole following single and multiple intravenous infusion in healthy Japanese adult
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for single dose:Cmax</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for single dose:AUClast</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for single dose:AUC0-6</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for single dose:Tmax</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for multiple dose:Ctrough</measure>
    <time_frame>prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for multiple dose:Cmax</measure>
    <time_frame>Day 8 to Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for multiple dose:AUC0-6</measure>
    <time_frame>Day 8 to Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for multiple dose:Tmax</measure>
    <time_frame>Day 8 to Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metronidazole pharmacokinetic parameters for multiple dose:CL</measure>
    <time_frame>Day 8 to Day 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: Cmax</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: AUClast</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: AUC0-6</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: Tmax</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Ctrough</measure>
    <time_frame>prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Cmax</measure>
    <time_frame>Day 8 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: AUC0-6</measure>
    <time_frame>Day 8 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Tmax</measure>
    <time_frame>Day 8 to Day 9</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole IV 500 mg</intervention_name>
    <description>On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.</description>
    <arm_group_label>1.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male and/or female subjects.

        Exclusion Criteria:

          -  Subject with evidence or history of clinically significant hematological, renal,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
             neurologic, or allergic disease (including drug allergies, but excluding untreated,
             asymptomatic, seasonal allergies at the time of dosing).

          -  Subject with history of regular alcohol consumption exceeding 7 drink/week for females
             or 14 drinks/week for males [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL)
             of beer or 1.5 ounces (45 mL) of hard liquor] within 6 months of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6831006&amp;StudyName=A%20Study%20To%20Assess%20The%20Safety%2C%20Tolerability%20And%20Pharmacokinetics%20Of%20Metronidazole%20Injection%20In%20Healthy%20Japanese%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>September 27, 2011</last_update_submitted>
  <last_update_submitted_qc>September 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metronidazole infusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

